Biopharmaceuticals
HIV/AIDS
FDA
News Release - June 27, 2007
FDA Priority Review Granted for ISENTRESS(TM) (raltegravir), Merck's Investigational Integrase Inhibitor for HIV
Source: Merck
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.